Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg
-
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK company, announced that the FDA has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
-
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share
-
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK announced it won't participate in Human Genome Sciences strategic alternatives review process
-
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1/05, accountable for medical governance & patient safety
-
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GSK announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join Board with effect from 1 July 2012 as Non-Executive Directors.
-
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
GSK and Yale established a drug discovery research collab to design a potential class of medicines that degrade disease-causing proteins.
-
GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)
GSK announced today that the EC has granted marketing authorisation for Nimenrix for immunisation against invasive meningococcal disease
-
GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry
GSK & University of Nottingham formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence
-
Children in Ghana to be vaccinated against diarrhoeal disease with the introduction of GSK’s Rotarix™ vaccine
GSK welcomes GAVI announcement that rotavirus vaccine, Rotarix, will be introduced into national vaccination programme in Ghana.
-
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
GSK announced the U.S. FDA has approved Votrient for the treatment of soft tissue sarcoma who have received prior chemotherapy.
-
Results announcement for the first quarter 2012
Sales growth of +2% CER Further R&D delivery, operational leverage returns to shareholders. Core EPS 27.3p (+7%), dividend up 6% to 17p
-
GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for £164 million
GSK announced it's reached agreement to divest non-core OTC brands in its international markets to Aspen for 163;164 million in cash.
-
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
GSK confirms it made an offer to the Board of Directors of HGS on 11/04 proposing to acquire all of the outstanding shares for US$13.00
-
GSK provides update on corporate responsibility commitments in 2011 report
GSK published its Corporate Responsibility Report, reiterating commitments to operate responsibly & transparently
-
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
GSK today announced that topline results have been received from seven of the eight Harmony Phase III studies investigating albiglutide.
-
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.
-
GlaxoSmithKline to increase its ownership in Theravance
GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a total investment of $212,887,000.
-
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK & THNX announced study results for Relovair in patients with COPD evaluating the efficacy compared to placebo in treatment of asthma
-
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed it will invest over 163m in the UK manufacturing sites to increase production of pharmaceutical products & vaccines
